The inconsistent findings highlight the complexity of vitamin D’s role in cancer progression, influenced by baseline vitamin D status, tumor heterogeneity, VDR expression, and potential gene environment interactions, underscoring the necessity for well-powered, biomarker-driven trials. This evidence concerns the gene VDR and neoplasm.